ECSP23049100A - Composición de péptidos para inmunoterapia - Google Patents
Composición de péptidos para inmunoterapiaInfo
- Publication number
- ECSP23049100A ECSP23049100A ECSENADI202349100A ECDI202349100A ECSP23049100A EC SP23049100 A ECSP23049100 A EC SP23049100A EC SENADI202349100 A ECSENADI202349100 A EC SENADI202349100A EC DI202349100 A ECDI202349100 A EC DI202349100A EC SP23049100 A ECSP23049100 A EC SP23049100A
- Authority
- EC
- Ecuador
- Prior art keywords
- immunotherapy
- hemoglobin
- subunit
- peptide composition
- alpha
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 102000001554 Hemoglobins Human genes 0.000 abstract 3
- 108010054147 Hemoglobins Proteins 0.000 abstract 3
- 102000044159 Ubiquitin Human genes 0.000 abstract 2
- 108090000848 Ubiquitin Proteins 0.000 abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract 2
- 239000000178 monomer Substances 0.000 abstract 2
- 101710197633 Actin-1 Proteins 0.000 abstract 1
- 102100031366 Ankyrin-1 Human genes 0.000 abstract 1
- 101710191059 Ankyrin-1 Proteins 0.000 abstract 1
- 102100035037 Calpastatin Human genes 0.000 abstract 1
- 102000000989 Complement System Proteins Human genes 0.000 abstract 1
- 108010069112 Complement System Proteins Proteins 0.000 abstract 1
- 102400000524 Fibrinogen alpha chain Human genes 0.000 abstract 1
- 101710137044 Fibrinogen alpha chain Proteins 0.000 abstract 1
- 108090000144 Human Proteins Proteins 0.000 abstract 1
- 102000003839 Human Proteins Human genes 0.000 abstract 1
- 101710196266 Protein 4.1 Proteins 0.000 abstract 1
- 102100031952 Protein 4.1 Human genes 0.000 abstract 1
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 abstract 1
- 102100034998 Thymosin beta-10 Human genes 0.000 abstract 1
- 102100035000 Thymosin beta-4 Human genes 0.000 abstract 1
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 1
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 1
- 108010044208 calpastatin Proteins 0.000 abstract 1
- ZXJCOYBPXOBJMU-HSQGJUDPSA-N calpastatin peptide Ac 184-210 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(C)=O)[C@@H](C)O)C1=CC=C(O)C=C1 ZXJCOYBPXOBJMU-HSQGJUDPSA-N 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000001086 cytosolic effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 150000002333 glycines Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108010044465 thymosin beta(10) Proteins 0.000 abstract 1
- 108010079996 thymosin beta(4) Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Es un objeto de la presente invención proporcionar una composición de péptidos con efectos inmunomoduladores para inmunoterapia que no presente variabilidad en el contenido de péptidos de acuerdo con su origen celular y método de fabricación. Para ello, se ha inventado una composición de péptidos con efectos inmunomoduladores que comprende el monómero completo de Ubiquitina humana (Ub) y una variante del monómeno de Ubiquitina humana que carece de dos glicinas terminales (Ub(-GG)). La composición de péptidos para inmunoterapia puede comprender adicionalmente por lo menos un fragmento de las siguientes proteínas humanas: Anquirina-1, Proteína 4.1, Subunidad Alfa de Hemoglobina, Subunidad Beta de Hemoglobina, Subunidad Delta de Hemoglobina, Proteína C3 del complemento, Calpastatina, Alfa-Sinucleína, Cadena Alfa del Fibrinógeno, Actina Citoplasmática 1, Timosina Beta-4, Timosina Beta-10, o Zixina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2020/061715 WO2022123298A1 (es) | 2020-12-09 | 2020-12-09 | Composición de péptidos para inmunoterapia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23049100A true ECSP23049100A (es) | 2023-09-29 |
Family
ID=81973291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202349100A ECSP23049100A (es) | 2020-12-09 | 2023-06-30 | Composición de péptidos para inmunoterapia |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240101622A1 (es) |
| EP (1) | EP4260867A4 (es) |
| AR (1) | AR124251A1 (es) |
| CA (1) | CA3201769A1 (es) |
| CO (1) | CO2023009006A2 (es) |
| CR (1) | CR20230240A (es) |
| CU (1) | CU20230030A7 (es) |
| DO (1) | DOP2023000120A (es) |
| EC (1) | ECSP23049100A (es) |
| GB (1) | GB2616198A (es) |
| PE (1) | PE20231510A1 (es) |
| WO (1) | WO2022123298A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024074870A1 (es) * | 2022-10-06 | 2024-04-11 | Instituto Politecnico Nacional | Composición veterinaria de péptidos para inmunoterapia |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7262162B2 (en) * | 2002-08-21 | 2007-08-28 | University Of Heidelberg | Ubiquitin and ubiquitin related molecules for treatment and prevention of harmful activation of the immune system |
| MX338863B (es) * | 2011-12-16 | 2016-05-01 | Inst Politecnico Nacional | Metodo de obtencion de extracto dializable de leucocitos. |
-
2020
- 2020-12-09 CA CA3201769A patent/CA3201769A1/en active Pending
- 2020-12-09 CU CU2023000030A patent/CU20230030A7/es unknown
- 2020-12-09 PE PE2023001829A patent/PE20231510A1/es unknown
- 2020-12-09 CR CR20230240A patent/CR20230240A/es unknown
- 2020-12-09 EP EP20964997.9A patent/EP4260867A4/en active Pending
- 2020-12-09 US US18/266,419 patent/US20240101622A1/en active Pending
- 2020-12-09 WO PCT/IB2020/061715 patent/WO2022123298A1/es not_active Ceased
- 2020-12-09 GB GB2308824.8A patent/GB2616198A/en not_active Withdrawn
-
2021
- 2021-12-06 AR ARP210103384A patent/AR124251A1/es unknown
-
2023
- 2023-06-09 DO DO2023000120A patent/DOP2023000120A/es unknown
- 2023-06-30 EC ECSENADI202349100A patent/ECSP23049100A/es unknown
- 2023-07-05 CO CONC2023/0009006A patent/CO2023009006A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB2616198A (en) | 2023-08-30 |
| DOP2023000120A (es) | 2024-01-31 |
| AR124251A1 (es) | 2023-03-01 |
| CA3201769A1 (en) | 2022-06-16 |
| US20240101622A1 (en) | 2024-03-28 |
| GB202308824D0 (en) | 2023-07-26 |
| CR20230240A (es) | 2023-10-23 |
| PE20231510A1 (es) | 2023-09-26 |
| EP4260867A4 (en) | 2024-10-23 |
| CO2023009006A2 (es) | 2023-10-30 |
| CU20230030A7 (es) | 2024-01-10 |
| WO2022123298A1 (es) | 2022-06-16 |
| EP4260867A1 (en) | 2023-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109274A2 (es) | Composición que comprende uno o más fragmentos de péptido intestinal vasoactivo (vip) y su uso para la fabricación de un medicamento | |
| ES2539812T3 (es) | Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos | |
| JOP20200251A1 (ar) | نظائر glp-1 جديدة | |
| MA52141A (fr) | Composition vétérinaire comprenant de la superoxyde dismutase et au moins un hydrolysat de protéines riche en peptides bioassimilables | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| EA201892671A1 (ru) | Пегилированный свиной интерферон и способы его применения | |
| AR113455A1 (es) | Proteínas inmunomoduladoras de variantes del ligando de icos y composiciones y métodos relacionados | |
| BR112018000660A2 (pt) | peptídeos anti-inflamatórios e seu uso | |
| CO2021014778A2 (es) | Subunidad s1 modificada de la proteína de espícula de coronavirus | |
| CO2023009006A2 (es) | Composición de péptidos para inmunoterapia | |
| CO2018011733A2 (es) | Composición farmacéutica | |
| MX2021000788A (es) | Composiciones de anticuerpos del receptor de fc (fcrn). | |
| NO20070296L (no) | Oligomere peptider og deres anvendelse for behandling av HIV infeksjoner | |
| CO2021017664A2 (es) | Péptidos | |
| DE602004028246D1 (de) | Analoga von peptiden der relaxin-superfamilie | |
| EP3849580A4 (en) | MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THEIR USE IN THE TREATMENT OF FIBROSIS | |
| ECSP066495A (es) | Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv) | |
| BR112021016727A2 (pt) | Hidrolisados de proteína com rendimento aumentado de aminoácido n-terminal | |
| MX2025002921A (es) | Composiciones de péptidos y fragmentos de proteínas de fibroína | |
| CL2023001668A1 (es) | Composición de péptidos para inmunoterapia | |
| BRPI0510016A (pt) | vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina | |
| ATE355302T1 (de) | N-substituierte d-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation | |
| ATE549346T1 (de) | Chemische modifikation von proteinen | |
| ECSP24035715A (es) | Composición para detectar el virus del síndrome de las manchas blancas y método para detectarlo | |
| WO2024030977A3 (en) | Novel melanocortin analogs |